Disease Activity Score 28-ESR bears a similar relationship to treatment decisions across different rheumatologists, but misclassification is too frequent to replace physician judgement

Rheumatology

Volumn 47, Issue 4, 2008, Pages 514-518

  Taylor, Will J ^a,b   Harrison, A A ^a,b   Highton, J ^a,c   Chapman, P ^d   Stamp, L ^d,e   Dockerty, J ^c   McQueen, F ^f   Jones, P B B ^f,g   Ching, D ^h   Porter, D ⁱ   Rajapakse, C ^b   Rudge, S R ^b   Taylor, G ^j   Kumar, S ^k   Macedo, T ^k   Sew Hoy, M ^l  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Hutt Valley District Health Board   (New Zealand)

^c Otago District Health Board   (New Zealand)

^d CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g QE Health   (New Zealand)

^h South Canterbury District Health Board   (New Zealand)

ⁱ Nelson Malborough District Health Board   (New Zealand)

^j Wanganui District Health Board   (New Zealand)

^k Division of Medicine Emergency and Integrated Care   (New Zealand)

^l NONE   (New Zealand)

more..

Author keywords

Disease activity score; Health status; Methodology; Physician factor; Psychometrics; Reliability; Remission criteria; Rheumatoid arthritis; Treatment decisions; Validity

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; RELIABILITY; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; AGED; DECISION MAKING; HOSPITALIZATION; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOMETRY;

ANTIRHEUMATIC AGENT;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DECISION MAKING; FEMALE; HUMANS; JUDGMENT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 43049161381     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken004     Document Type: Article

References (14)

1. Fransen J, Moens HB, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: A multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8.
2. Creemers MC, Fransen J, de Groot-Vos EH, Welsing P, Kievit W, van Riel PL. Implementation of the DAS28 as a routine assessment in daily clinical practice. Ann Rheum Dis 2005;64(Suppl. 3):603.
3. Smolen JS, Aletaha D. Target remission. The Rheumatologist 2007;1:14-16.
4. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9.
5. Ledingham J, Deighton C, on behalf of the British Society for Rheumatology Standards GaAWG.Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
6. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
7. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
8. Gardiner PV, Bell AL, Taggart AJ et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:506-7.
9. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic - discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52:3873-9.
10. Fransen J, Welsing PMJ, De Keijzer RMH, Van Riel PLCM. Development and validation of the DAS28 using CRP. Ann Rheum Dis 2003;62(Suppl. 1):10.
11. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of Disease Activity Score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9.
12. Saraux A, Devauchelle, Pensec V, Engerran L, Flipo RM. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: Results of the PRISME survey. J Rheumatol 2006;33:1258-65.
13. Vander Cruyssen B, Van Looy S, Wyns B et al. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: Validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005;7:R1063-71.
14. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: A comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41.